Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pain Therapeutics Confident It Has US Approval Pathway Set For Remoxy ER

Executive Summary

Biotech says it can complete two FDA-mandated studies by year-end and re-file the NDA rejected three times previously by the US agency. Pain Therapeutics also says it will not attempt to commercialize the abuse-deterrent opioid product without a partner.

Advertisement

Related Content

Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Pain's Remoxy Skips Over Panel On Rocky Road To Market
Never Surrender: Pain Therapeutics Eyes 2016 Remoxy Filing
Targiniq Review Shows How High FDA’s CV Safety Bar Is For Opioid Antagonists

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel